"10.1371_journal.pone.0089615","plos one","2014-02-24T00:00:00Z","Dov B Ballak; Peter van Essen; Janna A van Diepen; Henry Jansen; Anneke Hijmans; Tetsuya Matsuguchi; Helmut Sparrer; Cees J Tack; Mihai G Netea; Leo A B Joosten; Rinke Stienstra","Department of Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands; Institute for Genomic and Metabolic Disease, Radboud University Medical Centre, Nijmegen, The Netherlands; Nijmegen Institute for Infection Inflammation and Immunity, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Oral Biochemistry, Field of Developmental Medicine, Kagoshima University, Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan; Novartis Pharma AG, Basel, Switzerland; Department of Human Nutrition, Wageningen University and Research Centre, Wageningen, The Netherlands","Conceived and designed the experiments: DB PvE HS CT MN LJ RS. Performed the experiments: DB PvE JvD HJ AH. Analyzed the data: DB JvD CT MN LJ RS. Contributed reagents/materials/analysis tools: TM HS. Wrote the paper: DB JvD CT MN LJ RS.","One of the authors is an employee of the Novartis Pharma AG, Basel, Switzerland. However, neither he or the company have any competing interests in this study. Additionally, no patents or marketing products have been used in the current study, nor will the company benefit from the results reported in this manuscript. Helmut Sparrer has provided the authors with the unique MAP3K-deficient mouse model. and contributed to writing and revising of the manuscript. Novartis does not conduct any research on MAP3K and has no intellectual or financial interests. Therefore, the authors herby confirm that this does not alter adherence to all the PLOS ONE policies on sharing data and materials.","2014","02","Dov B Ballak","DBB",11,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
